FAQs
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Dianthus Therapeutics’ transfer agent is Computershare.
150 Royall Street
Canton, MA 02021
800-446-2617
The anticipated material U.S. federal income tax consequences of (i) the merger between Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) and Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.), (ii) the 1-for-16 reverse stock split effected by Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) on September 11, 2023, and (iii) the receipt of the contingent value rights (“CVRs”) distributed by Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) distributed on September 14, 2023, were summarized and discussed in the definitive proxy statement/prospectus filed with the Securities and Exchange Commission in connection with the merger (the “Proxy Statement / Prospectus”), which can be viewed here.
A U.S. Internal Revenue Service Form 8937 (Report of Organizational Actions Affecting Basis of Securities) for each of the merger and name change, the reverse stock split, the distribution of the CVRs, and the exchange of shares of Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.) for shares of Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.) at the effective time of the merger can be found at the following links:
Form 8937 for Dianthus Therapeutics, Inc. (F/K/A Magenta Therapeutics, Inc.); and
Form 8937 for Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.).
For a complete description of the anticipated material U.S. federal income tax consequences of the receipt of CVRs by stockholders, see the section entitled “Agreements Related to the Merger—Contingent Value Rights Agreement—Material U.S. Federal Income Tax Consequences of the CVRs to Holders of Magenta Common Stock” beginning on page 208 of our Proxy Statement / Prospectus, which can be viewed here.
PLEASE CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL INCOME AND OTHER U.S. FEDERAL, STATE, LOCAL OR NON-U.S. TAX CONSEQUENCES OF THEREVERSE STOCK SPLIT, THE RECEIPT OF THE CVRs, OR THE MERGER, AS APPLICABLE TO YOUR OWN PERSONAL CIRCUMSTANCES.